S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
Laser breakthrough could send stock soaring 2,467% (Ad)
2 Stocks to Benefit from the Aging Population
3 Warren Buffett Stocks that are Moving into the Buy Zone
Laser breakthrough could send stock soaring 2,467% (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
3 Stocks That Really, Really Need the Defense Bill to Pass
Laser breakthrough could send stock soaring 2,467% (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
Laser breakthrough could send stock soaring 2,467% (Ad)
2 Stocks to Benefit from the Aging Population
3 Warren Buffett Stocks that are Moving into the Buy Zone
Laser breakthrough could send stock soaring 2,467% (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
3 Stocks That Really, Really Need the Defense Bill to Pass
Laser breakthrough could send stock soaring 2,467% (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
Laser breakthrough could send stock soaring 2,467% (Ad)
2 Stocks to Benefit from the Aging Population
3 Warren Buffett Stocks that are Moving into the Buy Zone
Laser breakthrough could send stock soaring 2,467% (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
3 Stocks That Really, Really Need the Defense Bill to Pass
Laser breakthrough could send stock soaring 2,467% (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Hanes Worth More than the Sum of Its Parts?
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
Laser breakthrough could send stock soaring 2,467% (Ad)
2 Stocks to Benefit from the Aging Population
3 Warren Buffett Stocks that are Moving into the Buy Zone
Laser breakthrough could send stock soaring 2,467% (Ad)
3 Reasons Unity Software Is Ready to Rally 38%
3 Stocks That Really, Really Need the Defense Bill to Pass
Laser breakthrough could send stock soaring 2,467% (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Is Hanes Worth More than the Sum of Its Parts?
NASDAQ:BEAM

Beam Therapeutics (BEAM) Stock Forecast, Price & News

$23.60
+0.59 (+2.56%)
(As of 09/26/2023 ET)
Compare
Today's Range
$22.80
$24.28
50-Day Range
$23.01
$32.46
52-Week Range
$22.52
$54.30
Volume
843,543 shs
Average Volume
876,288 shs
Market Capitalization
$1.87 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$63.82

Beam Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.70 Rating Score
Upside/​Downside
170.4% Upside
$63.82 Price Target
Short Interest
Bearish
16.58% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.39mentions of Beam Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$5.03 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($5.06) to ($5.64) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.94 out of 5 stars

Medical Sector

693rd out of 964 stocks

Biological Products, Except Diagnostic Industry

112th out of 157 stocks


BEAM stock logo

About Beam Therapeutics (NASDAQ:BEAM) Stock

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 and BEAM-102 for the treatment of sickle cell disease beta thalassemia; BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease; and the Institute of Molecular and Clinical Ophthalmology Basel for treatment of impaired vision and blindness. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

BEAM Price History

BEAM Stock News Headlines

This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
Bernstein Keeps Their Hold Rating on Beam Therapeutics (BEAM)
Citi Remains a Buy on Beam Therapeutics (BEAM)
Beam Therapeutics Q2 Loss Widens But Beats Estimates
See More Headlines
Receive BEAM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Beam Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BEAM Company Calendar

Last Earnings
8/08/2023
Today
9/27/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BEAM
Fax
N/A
Employees
532
Year Founded
2017

Price Target and Rating

Average Stock Price Forecast
$63.82
High Stock Price Forecast
$105.00
Low Stock Price Forecast
$35.00
Forecasted Upside/Downside
+170.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.70
Research Coverage
10 Analysts

Profitability

Net Income
$-289,090,000.00
Net Margins
-408.13%
Pretax Margin
-372.07%

Debt

Sales & Book Value

Annual Sales
$60.92 million
Book Value
$10.41 per share

Miscellaneous

Free Float
75,715,000
Market Cap
$1.87 billion
Optionable
Not Optionable
Beta
1.62

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. John M. Evans M.B.A.Mr. John M. Evans M.B.A. (Age 45)
    CEO & Director
    Comp: $1.11M
  • Dr. Giuseppe Ciaramella Ph.D. (Age 54)
    Pres
    Comp: $933.2k
  • Ms. Terry-Ann Burrell M.B.A.Ms. Terry-Ann Burrell M.B.A. (Age 46)
    CFO & Treasurer
    Comp: $711.15k
  • Dr. Feng Zhang Ph.D.
    Co-Founder
  • Dr. David R. Liu Ph.D.
    Co-Founder
  • Dr. J. Keith Joung M.D.
    Ph.D., Co-Founder
  • Dr. Nicole Gaudelli Ph.D.
    Co-Founder
  • Dr. Alexis Komor Ph.D.
    Co-Founder
  • Dr. Manmohan Singh Ph.D.
    Chief Technology Officer
  • Dr. Gopi Shanker Ph.D.
    Chief Scientific Officer













BEAM Stock - Frequently Asked Questions

Should I buy or sell Beam Therapeutics stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beam Therapeutics in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BEAM shares.
View BEAM analyst ratings
or view top-rated stocks.

What is Beam Therapeutics' stock price forecast for 2023?

10 Wall Street research analysts have issued 12-month price targets for Beam Therapeutics' shares. Their BEAM share price forecasts range from $35.00 to $105.00. On average, they predict the company's stock price to reach $63.82 in the next year. This suggests a possible upside of 170.4% from the stock's current price.
View analysts price targets for BEAM
or view top-rated stocks among Wall Street analysts.

How have BEAM shares performed in 2023?

Beam Therapeutics' stock was trading at $39.11 at the beginning of 2023. Since then, BEAM stock has decreased by 39.7% and is now trading at $23.60.
View the best growth stocks for 2023 here
.

When is Beam Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our BEAM earnings forecast
.

How were Beam Therapeutics' earnings last quarter?

Beam Therapeutics Inc. (NASDAQ:BEAM) posted its quarterly earnings data on Tuesday, August, 8th. The company reported ($1.08) EPS for the quarter, topping the consensus estimate of ($1.42) by $0.34. The firm had revenue of $20.12 million for the quarter, compared to analyst estimates of $17.32 million. Beam Therapeutics had a negative trailing twelve-month return on equity of 43.32% and a negative net margin of 408.13%. The firm's revenue was up 20.8% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.02) earnings per share.

What other stocks do shareholders of Beam Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Beam Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Editas Medicine (EDIT), Cisco Systems (CSCO), Block (SQ), Skyworks Solutions (SWKS), Akoustis Technologies (AKTS), Invitae (NVTA), QUALCOMM (QCOM) and Alector (ALEC).

When did Beam Therapeutics IPO?

(BEAM) raised $101 million in an initial public offering on Thursday, February 6th 2020. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and Barclays acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Beam Therapeutics' stock symbol?

Beam Therapeutics trades on the NASDAQ under the ticker symbol "BEAM."

Who are Beam Therapeutics' major shareholders?

Beam Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (11.00%), BlackRock Inc. (8.02%), Temasek Holdings Private Ltd (5.45%), State Street Corp (4.53%), Geode Capital Management LLC (1.67%) and Deep Track Capital LP (1.66%). Insiders that own company stock include Amy Simon, Fmr Llc, Giuseppe Ciaramella, Graham K Cooper, John M Evans, John M Evans and Terry-Ann Burrell.
View institutional ownership trends
.

How do I buy shares of Beam Therapeutics?

Shares of BEAM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Beam Therapeutics' stock price today?

One share of BEAM stock can currently be purchased for approximately $23.60.

How much money does Beam Therapeutics make?

Beam Therapeutics (NASDAQ:BEAM) has a market capitalization of $1.87 billion and generates $60.92 million in revenue each year. The company earns $-289,090,000.00 in net income (profit) each year or ($4.51) on an earnings per share basis.

How many employees does Beam Therapeutics have?

The company employs 532 workers across the globe.

Does Beam Therapeutics have any subsidiaries?
The following companies are subsidiares of Beam Therapeutics: Blink Therapeutics Inc..
Read More
How can I contact Beam Therapeutics?

Beam Therapeutics' mailing address is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. The official website for the company is www.beamtx.com. The company can be reached via phone at 857-327-8775 or via email at investors@beamtx.com.

This page (NASDAQ:BEAM) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -